Navigation Links
FDA Collaboration Seeks to Speed Development of Pneumococcal Vaccines for Children in Developing Countries
Date:2/1/2010

PATH supports FDA advancement of a key step in vaccine development

SILVER SPRING, Md., Feb. 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Worldwide, the bacterium also causes infections of the brain (meningitis), blood (sepsis), and middle ear (otitis media) and each year kills about 1 million children younger than 5 years of age. The collaboration aims to improve the techniques used to produce effective, safe, and affordable vaccines against pneumococcal disease for children in the developing world.

PATH is an international nonprofit organization based in Seattle that creates sustainable, culturally relevant, and affordable solutions to help communities worldwide to break cycles of poor health.

The collaborative project, expected to run for two years, is being conducted under the Cooperative Research and Development Agreement (CRADA) program. The program allows federal laboratories and businesses to form partnerships that help expedite research activities.

Under the agreement, PATH will help the FDA obtain materials needed for the agency to develop the conjugate vaccine technology. PATH also will provide approximately $480,000 to the FDA for the development of both the conjugation technology and tests to determine if the carrier proteins are properly linked to the polysaccharides.

The goal of the CRADA is to evaluate the application of Center for Biologics Evaluation and Research (CBER) conjugation technology to pneumococcal vaccines. If it holds promise for fulfilling the goal of providing safe, effective, and affordable pneumococcal vaccines, the CRADA permits transfer of the technology to the China National Biotec Group's Chengdu Institute of Biological Products, and eventually to groups in other developing countries as appropriate.

"CBER will use its scientific expertise to develop technology for a vaccine against pneumococcal disease that is safe and effective," said Karen Midthun, M.D., acting director of the FDA's CBER. "The collaboration with PATH is an example of how the FDA applies technologies it develops to public health issues in the United States and throughout the world under the agency's Critical Path Initiative."

The goal of the FDA's work is to improve the efficiency of a key technology in the development of pneumococcal conjugate vaccine candidates. The technology is used to link a piece of the bacterium's surface coating, a polysaccharide made up of long chains of sugars, to a special molecule called a carrier protein in a process called conjugation.

When carrier proteins are joined with the polysaccharides, they significantly increase the strength of the immune response. Without these proteins, the polysaccharides by themselves would not trigger an adequate immune response in young children.

CBER conjugation technology has already been used by the Meningitis Vaccine Project—a partnership between PATH and the World Health Organization—for the development of a conjugate vaccine to prevent meningococcal meningitis in Africa.

For more information:

Collaborative Opportunities –FDA Technology Transfer Program

http://www.fda.gov/ScienceResearch/CollaborativeOpportunities/default.htm

PATH Web site

http://www.path.org

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

RELATED LINKS
http://www.fda.gov/
http://www.path.org/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. American Red Cross and FedEx Announce Collaboration to Help Small Businesses Get Prepared for Disaster
3. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
4. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
5. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
6. London School of Hygiene to play key role in global collaboration on adverse drug reactions
7. Chemizon Announces Research Collaboration Expansion With Takeda
8. Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
9. American Diabetes Association Announces Three Year Collaboration With The Dignity Memorial(R) Network
10. Diet.com Enters Strategic Collaboration To Support Microsoft HealthVault
11. AMRI and Cystic Fibrosis Foundation Launch Major Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... thrilled to announce the ATA 2017 President’s Awards recipients, comprised of organizations ... superior healthcare delivery. , The ATA 2017 President’s Awards recognize individuals ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Excellence specializes in pelvic conditions and has helped many women become pregnant upon ... a combination of office-based and simple outpatient evaluations. We can provide the ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... for sponsors and CROs to speed clinical development, has released the industry’s ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management ...
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology: